Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PANOVA-4: TTFields + Atezolizumab + Gemcitabine + Nab-Paclitaxel in First-Line mPDAC
NCT06390059Phase 2Completed
- Sponsor
- NovoCure
- Start
- Aug 2023
- Primary completion
- Nov 2025
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
A Phase 2 trial of atezolizumab in pancreatic ductal adenocarcinoma (PDAC), sponsored by NovoCure. Started Aug 2023; status: completed.
02
Drugs
atezolizumab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06390059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06390059.